The drug has been reported to exhibit antiviral activity against influenza A and B viruses with IC50 values in the low micromolar range. In this arena, naproxen antagonized CRM1-mediated nuclear export of proteins of influenza A and B viruses. Naproxen also provided therapeutic protection to mice infected with influenza B virus [150,151]. In hospitalized patients with influenza, it was found that adding clarithromycin and naproxen to oseltamivir shortened the hospitalization time [150,151]. Naproxen also inhibited the replication of Zika virus by reducing the expression of AXL, the entry cofactor of Zika virus [152]. Naproxen’s antiviral activity against SARS-CoV-2 has also been proposed by a recent computational work and has been attributed its ability to bind to the viral nucleocapsid protein. In fact, it was recently reported that naproxen inhibits SARS-CoV-2 infection in Vero E6 cells and in reconstituted human airway epithelia with IC50 values comparable to those effective in influenza [153]. Lastly, similar to indomethacin, the anti-inflammatory effects of naproxen may also translate into beneficial effects in treating the cytokine storm of COVID-19.